Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Transformative nanotechnology drug delivery platform enabling eradication of micrometastases in ovarian cancer

Obiettivo

NaDeNo is a Norwegian biopharma company advancing a proprietary nanotechnology platform to transform local drug delivery and retention at disease sites. Originating from SINTEF, Europe’s leading research institute, NaDeNo builds on decades of nanotherapeutic expertise. Its lead program, PACAB-002, is a novel nanoformulation of cabazitaxel designed for intraperitoneal treatment of micrometastases in high-grade serous ovarian cancer (HGSOC)—a major unmet need where systemic therapies fail due to poor vascularization. By encapsulating the drug in poly(alkyl cyanoacrylate) (PACA) nanoparticles, PACAB-002 achieves efficient transport, tumour adhesion, and sustained local release, overcoming limitations of free drugs and conventional intraperitoneal formulations. Preclinical studies demonstrated 100% survival and a 97% tumour weight reduction compared to non-encapsulated cabazitaxel, highlighting its potential to reduce relapse rates and improve outcomes.

Our platform brings together multiple innovations that redefine how drugs can be formulated and delivered: 1) a unique ability to solubilize and encapsulate poorly soluble drugs with novel chemistries; 2) a proprietary one-step, low-cost, scalable manufacturing process; and 3) distinctive mode of action enabling receptor-independent tissue accumulation and retention. Beyond PACAB-002, the platform could unlock new therapeutic opportunities by reviving potent but poorly soluble compounds, for next-generation oncology and other hard-to-formulate treatments.

NaDeNo plans to initiate a phase 1/2a trial for PACAB-002 in 2H 2026, aiming for market entry in 2033. Financial projections model €4.2B lifetime revenues, with royalties reinvested into platform expansion. To achieve this, NaDeNo seeks EIC Accelerator support (€2.5M grant, €7.5M equity) to advance PACAB-002 into clinical development and establish a new standard of care for ovarian cancer.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-EIC-ACC - HORIZON EIC Accelerator

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-EIC-2025-ACCELERATOR-02

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

NADENO NANOSCIENCE AS
Contributo netto dell'UE
€ 2 499 999,00
Indirizzo
PROFESSOR BROCHS GATE 16
7030 TRONDHEIM
Norvegia
PMI
Sì
Regione
Norge Trøndelag Trøndelag
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
Nessun dato